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Purpose: Encourage prediabetes screening, testing, and referral to a CDC-recognized Diabetes 
Prevention Program (DPP) as a first-line treatment. Background: The prevalence of diabetes 
and prediabetes incidence is highest among Medicare-eligible Washingtonian patients, with 
19% and 16%, respectively. DPP results in a 71% reduction of diabetes incidence in 65 years 
and older. However, only 3% of healthcare sites screen, test, and refer to DPP. Design: Quality 
assessment with a descriptive quantitative evaluation method was conducted using 
Retrospective Chart Review for patients who visited Franciscan primary clinics from 
08/31/2019 to 08/31/2020. A total of 1250 Medicare patients were extracted from a convenient 
sample. Risk factors for prediabetes were identified for 224 patients, including, a first-degree 
family history of diabetes, history of hypertension, age, race/ethnicity, physical activity, sex, 
history of gestational diabetes, height, and weight and were entered into the online American 
Diabetes Association prediabetes risk-test. The number of patients who fulfilled the criteria for 
a diagnosis of prediabetes based on Fasting Plasma Glucose, Glycated Hemoglobin A1c and 
Random Glucose was 685. Four patients had mixed laboratory results and were excluded; the 
remaining 681 were considered for prediabetes management. The number of patients who did 
not fulfill laboratory criteria for prediabetes was 565. Results: All the 224 patients (100%) had 
risk-test scores of at least 5. The prevalence of misdiagnosis of blood glucose was 45.2%. All 
of the 681 patients (100%) meeting requirements of prediabetes were not referred to DPP. Only 
26 patients (3.8%) were managed by either metformin (3.1%) or referral to diabetes education 
(0.7%). Conclusion: Medicare patients at high risk are not routinely screened, tested, and 
managed by DPP, metformin, or diabetes education. Implication: Practice change needs 
assessment of PCP awareness about diabetes risk-test, prediabetes laboratory parameters, and 
management by referral to DPP.  
Key Words: Diabetes Prevention Program, Diabetes Risk-test, Prediabetes Lab Parameters. 
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Diabetes is a chronic disease that affects how the body metabolizes carbohydrates 
resulting in hyperglycemia. The condition is the seventh leading cause of death in the United 
States (Centers for Disease Control and Prevention, 2020). There are three main types of 
diabetes: type 2 accounting for 90 to 95%, type 1 accounting for 5-10%, and gestational 
diabetes. More than 122 million Americans live with diabetes (34.2 million), 20% of whom 
are unaware of their diagnosis, “and whereas 88 million live with prediabetes, nearly 85% of 
whom are unaware of their diagnosis” (Centers for Disease Control and Prevention, 2020). 
The lost wages, time at work, and medical costs in individuals with diabetes are twice as high 
as those without diabetes, accounting for $327 billion in health care costs each year (Centers 
for Disease Control and Prevention, 2020). Ultimately, the prevention of diabetes saves costs 
incurred for treating diabetes and its complications, including retinopathy, peripheral 
neuropathy, kidney disease, and cardiovascular diseases (Bansal, 2015). Additionally, early 
intervention in older adults prevents or slows the risk of all-cause dementia, Alzheimer 
disease and vascular dementia (American Diabetes Association, 2021).  
Prediabetes is a precursor state of high blood sugar with glycemic parameters above 
normal but not high enough to diagnose diabetes (Bansal, 2015). The definition of 
prediabetes lacks uniformity between international organizations. The American Diabetes 
Association (ADA) defines prediabetes as impaired fasting plasma glucose level (100-
125mg/dl), impaired 2-hour oral glucose tolerance test (140-200mg/dl), glycated hemoglobin 
A1c of 5.7-6.4%, and random glucose ≥140-199mg/dl (American Diabetes Association, 
2014). The World Health Organization (WHO), on the other hand, defines prediabetes with 
the same cut-off value for impaired 2-hour oral glucose tolerance test (140-199 mg/dl) but a 
higher cut-off value for impaired fasting glucose (110-125mg/dl) (World Health 
Organization, 2006). WHO does not consider random glucose and glycated hemoglobin A1c 




as a practical diagnostic test; the latter has potential interference with other hemoglobin 
variants such as sickle cell hemoglobin and fetal hemoglobin (World Health Organization, 
2006). Like the before ADA, Diabetes Canada 2018 Clinical Practice Guideline defines 
prediabetes based on FPG and A1c but with a higher cuff-value (110-125mg/dl) and 6.0-
6.4%, respectively (Punthakee, Goldenberg & Katz, 2018). To confirm the diagnosis of 
prediabetes after the initial abnormal test, providers need to repeat testing with the original 
screening test, run a different screening test with the initial specimen or collect another 
sample (American Diabetes Association, 2014) and rescreen the patient with repeat testing in 
3-6 months. If the screening test is within normal range, repeat testing in three years is 
recommended (American Diabetes Association, 2021).  
The United States Preventative Services Taskforce (USPSTF) recommends screening 
for abnormal blood glucose levels between the age of 40 and 70 years in individuals who are 
overweight or obese (United States Preventative Services Task Force, 2015), whereas ADA 
recommends screening starting at age 45 in all adults regardless of body weight. If screening 
is positive for prediabetes, the Centers for Disease Control and Prevention (CDC), 
International Diabetes Federation (IDF), ADA, and USPSTF recommend providers offer or 
refer patients to an intensive behavioral counseling intervention that promotes a healthful diet 
and physical activity.  If left unscreened, prediabetic patients develop type II diabetes in 3-8 
years (Herman et al., 2015), 50% of which remain undiagnosed and untreated until they 
develop complications later in life (International Diabetes Federation, 2017).  
Overwhelming evidence from worldwide studies indicates lifestyle intervention with 
diet, exercise, or a combination of diet and exercise enhanced by prediabetes education 
prevents or delays the risk of developing diabetes. For example, lifestyle intervention reduced 
the risk by 46% with exercise alone, by 42% with diet and exercise, and 31% with diet alone 
in 577 Chinese individuals over the Da Qing Study's six-year period (Pan et al., 1997). 




Another diabetes prevention study conducted in Europe, among Finish individuals, showed 
lifestyle intervention with significant reduction in weight, glycemia, and lipemia over three 
years (Lindström et al., 2003). The diabetes prevention program (DPP), a randomized clinical 
trial that compared lifestyle intervention with metformin and placebo in multiethnic groups in 
3234 US adults with prediabetes, reinforces the importance of lifestyle change in the Chinese 
and Finnish studies. The DPP study involved 68% women and 45% minorities.  After 
followed up for 2.8 years, the DPP reduced the incidence of diabetes by 58% in the lifestyle 
intervention group and 31% in the metformin group (Knowler et al., 2002). The reduction of 
incidence of diabetes by DPP was highest (71%) in US adults age 65 and older with 
prediabetes.  However, 90% of older adults are unaware that they have prediabetes (Kalyani, 
Corriere, Donner, & Quartuccio, 2018).  If a DPP is not available in the area, or patients are 
not willing to participate in the program, providers can refer patients to diabetes educators 
(Sherr & Lipman, 2013). Primary care providers can also initiate metformin treatment in 
prediabetic patients younger than 60 years, or BMI ≥35 kg/m2, and in women with 
gestational diabetes mellitus (American Diabetes Association, 2021). Alternatively, they can 
refer to medical nutrition therapy or provide a point of care brief counseling (American 
Medical Association, 2018).   
Problem Statement  
In Washington State, diabetes prevalence increased from 4% in 1993 to 9% in 2016, 
with the highest (19%) among Medicare eligible patients (Washington State Health 
Assessment, 2018). The same survey showed an increase in prediabetes incidence during 
2011-2016 from 7 to 8%, with the highest (16%) among Medicare eligible patients. 
 Unfortunately, the incidence of prediabetes is highest among adults 65 years and older 
despite their high awareness of prediabetes in this age group (Washington State Health 
Assessment, 2018). One-third of all people in Washington have prediabetes, 70% of which 




could proceed to type 2 diabetes in five years, however most of them are unaware of their 
prediabetes status (Diabetes Epidemic and Action Report, 2019).  
Background 
Diabetes affects more than 25% of Americans aged 65 years and above (Andes et al., 
2019). Among Medicare beneficiaries, diabetes prevalence increased from 23% in 2001 to 
32% in 2012 and remained stable until 2015 (Centers for Disease Control and Prevention, 
2020). Incidence of diabetes among Medicare patients increased from 3.4% in 2001 to 4 % in 
2007 and then steadily declined to 3% in 2015 (Andes et al., 2019). The decline in the 
incidence of diabetes in older population is attributed to reduced consumption of dairy 
products and sugar-added beverages, and improved physical activity (Kit, et al., 2013; Ussery 
et al., 2017). In the last two decades, however, prevalence of diagnosed diabetes in adults 
doubled with aging and increased obesity (Center for Disease Control and Prevention, 2020). 
Approaches proven to curb progression of prediabetes to diabetes are CDC-approved DPP, 
metformin treatment, medical nutrition therapy, diabetes education, or point-of-care brief 
counseling on lifestyle change (American Medical Association, 2018). 
The National DPP is the most effective evidence-based lifestyle change program that 
reduces the incidence of diabetes by 71% among individuals age 65 years and above when 
they attain a minimum of 5% weight loss (Kalyani, Corriere, Donner, & Quartuccio, 2018). 
The USPSTF found no evidence that the lifestyle change interventions will harm the DPP 
participants (US Preventive Services Task Force, 2016). However, over 60% of primary care 
providers are not aware of the DPP (Nhim et al., 2018).   
In May 2017, the Washington State Institute for Public Policy analysis predicted that 
the net benefit from the DPP is $13,000 per participant, including $4,875 of benefit for 
taxpayers for each program participant (Diabetes Epidemic and Action Report, 2017). 
However, only 8 (3%) healthcare sites out of 243 routinely screen for prediabetes, order lab 




tests, and refer to the DPP in the state of Washington (Diabetes Epidemic and Action Report, 
2019), indicating that primary care providers in the rest 97% of healthcare sites do not refer 
their patients to DPP.  
More than one-quarter of adults with prediabetes express interest in participating in a 
diabetes prevention programs, but few are being referred by their primary care providers 
(Venkataramani et al., 2019). There is a need to further assess existing practices of 
prediabetes screening, testing and referral to the CDC-recognized lifestyle change program 
(Nhim et al., 2018) and enhance program referral and access to diabetes prevention programs 
(Venkataramani et al., 2019). Practices that used retrospective chart review (RCR) identified 
more Medicare-eligible patients with prediabetes and increased referral to DPP than those 
using a routine point of care testing alone (Holliday et al., 2019). Additionally, creating a 
clinical registry to screen and track patients with prediabetes has resulted in more individuals 
with prediabetes being referred to diabetes prevention programs (American Medical 
Association, 2017).   
Purpose and Aim 
The purpose of this project is to encourage screening, testing, and referral to a DPP as 
a first-line treatment for prediabetes. The aims of the project through a retrospective chart 
review are 1) to determine prediabetes risk-test scores by assessing risk factors for 
prediabetes; 2) to determine the prevalence of misdiagnosis of blood glucose levels; and 3) to 
assess types of prediabetes management ordered by providers at the Franciscan Primary care 
clinics. 
Theoretical Framework  
The Donabedian model of quality assessment was applied as a conceptual framework 
for the project (Donabedian, 1988). An electronic medical record system was used as a 
resource to represent the structure of patient care delivery. The providers' routine practice to 




assess for prediabetes risk, order laboratory tests for abnormal glucose, and management of 
prediabetes was used as the framework's process. The outcomes of the framework were 
misdiagnosis of prediabetes and untreated prediabetes. 
Methodology 
Study Design 
 A quality assessment project with a descriptive quantitative evaluation method was 
conducted using a RCR (Matt & Matthew, 2013) for patients who visited Franciscan Medical 
Group (FMG) primary clinics between 08/31/2019 to 08/31/2020. 
Setting 
Catholic Health Initiative (CHI) Franciscan Healthcare System of Washington has 29 
primary care clinics served by an estimated 205 primary care providers of FMG (Franciscan 
Medical Group). Out of which 165 of the providers are physicians, and the remaining 40 are 
nurse practitioners and physician assistants. The number of diabetes educators who serve 
within the healthcare system is estimated to be 8-10. The total number of Medicare patients 
who visited the primary clinics within the healthcare system between 2013-2020 was 18752, 
with an average annual patient number of 2344.  
Sample 
The inclusion criteria included age 65 years and above, body mass index (BMI)≥25 
kg/m2 (≥23 kg/m2, if Asian), Medicare or Medicare Advantage health plan, and laboratory 
test results within the last one year of Fasting Plasma Glucose (FPG) range within 100-
125mg/dl, or A1c range within 5.7%-6.4%, or 2-hour Oral Glucose Tolerance Test (OGTT) 
range within 140-200 mg/dl), or history of gestational diabetes, and both sexes of all 
racial/ethnic groups. Exclusion criteria included those individuals with type 1 or type 2 
diabetes, end-stage renal disease or long-term (current) use of insulin (Appendix A; Center 
for Medicare and Medicaid Services, 2018). Published literature indicates a minimum of 5-10 




chart reviews per variable is required to obtain results that are likely to be both valid and 
clinically useful (Johnston et al., 2019). Johnson et al. further indicated that 100 retrospective 
chart reviews are sufficient for summarizing prediabetes management categories. 
Demographic 
The majority of 1250 Medicare patients reviewed in this quality assessment project 
were White or Caucasian, 1066 (85.28%), followed by Asians, Blacks, and Native Hawaiian, 
and they were overweight, obese, or extremely obese (Table 1). 
Table 1.0  




Sex Female 679 54.32  
Male 571 45.68 
Race White/Caucasian 1066 85.28  
Asians 47 3.76  
Blacks 42 3.36  





Other 21 1.68  
Native Hawaiian 7 0.56 




Hispanic  33 2.64  















  A convenience sample of 18,752, Medicare patient data was retrieved from Epic, an 
electronic charting system. Out of 18,752 Medicare patients, 17,502 were excluded for test 
results older than one year, diagnosis of type 1 or type 2 diabetes, long-term (current) insulin 




use, or end-stage renal disease. The remaining 1,250 Medicare patients who sought care at 
CHI Franciscan Primary Care Clinics within the last year between 08/31/2019 to 08/31/2020.  
Out of 1,250 Medicare patients, 565 were excluded from consideration for prediabetes 
management because they had either normal A1c (<5.7%, n=323), A1c within diabetes range 
(>6.4%, n=17), or were not tested by A1c (n=225). None of the 565 patients were tested with 
2-hour OGTT for prediabetes. Out of the 225 patients not tested by A1c, only one patient was 
tested by FPG and had normal blood glucose result; the remaining, 224 patients were tested 
only with random glucose and assessed for CDC prediabetes risk-test score. Samples 
collected to assess for prediabetes risk were first-degree family history of diabetes, history of 
hypertension, age, race/ethnicity, physical activity, sex, height, and weight.  
A total of 685 out of the 1250 patients fulfilled laboratory inclusion criteria for 
prediabetes defined as FPG 100-125mg/dl or A1c 5.7%-6.4%. Four patients were excluded 
for having A1c levels within the diabetes range; the remaining 681 patients were considered 
for prediabetes management. None of these patients were tested with 2-hour OGTT for 
prediabetes. 
Data Collection Procedure 
Before collection of data, the Institutional Review Board (IRB) exempt approval was 
obtained from the CHI Franciscan Healthcare System to protect human subjects. The 
retrospective health record data was collected anonymously with no patient data identifiers. 
With data analysts' help at the CHI healthcare system, inclusion and exclusion criteria were 
entered into the Epic electronic health record system. The data analyst exported the data into 
an excel spreadsheet, coded the medical record number (MRN) of each patient with a specific 
identification number, and then removed patient identifiers. 
Data on, 1250, Medicare patients who visited primary care clinics of the CHI 
Franciscan health care system within the last year between 08/31/2019 and 08/31/2020 was 




filtered using an excel spreadsheet. Medicare patients (n=681) who fulfilled the inclusion 
criteria for prediabetes management were filtered within excel by the provider’s plan and 
categorized into prediabetes management types: DPP, Metformin, diabetes education, or 
medical nutrition therapy (figure 1 & figure 2).  
Medicare patients (n=565) who did not fulfill laboratory inclusion criteria for 
prediabetes were identified by laboratory test as having A1c in diabetic range, normal A1c, 
no A1c test, normal fasting plasma glucose, random glucose within diabetes range, or no 
laboratory glucose test within the last one year. However, these patients were assessed for 
misdiagnosis of prediabetes by filtering based on the laboratory test result and International 
Classification of Diseases -Tenth Revision (ICD-10 codes) such as R73.01, R73.02, R73.03, 
R73.09 which were retrospectively entered into Epic by providers. Out of the 565 Medicare 
patients, 224 were tested only by random glucose or were not tested (figure 1). The 224 were 
filtered within Excel by the risk factors for prediabetes, and the risk factors were entered into 
the online CDC prediabetes risk-test calculator (appendix B), and online scores 
from https://www.diabetes.org/risk-test were manually entered into an excel spreadsheet 















Figure 1. Steps in Data Collection Procedure.  
Review Provider’s Plan
Categorize as referral to DPP, Diabetes Education, Medical Nutrition Therapy, metformin treatment, a brief 
lifestyle change counseling. 
Review Provider’s Assessment (ICD-9 and ICD-10 codes)
Assess diagnosis of prediabetes
Review Logical Observation Identifiers Names (LOIN)
Identify abnormal glucose lab test results
Chart Reporting Tool
Assess risk factors for prediabetes Online ADA Prediabetes risk-test score 
https://www.diabetes.org/risk-test





                   Figure 2. Flowchart of sample collection procedure  
Data Analysis 
Data was exported from Epic into an Excel spreadsheet.  All study subjects with 
missing data and outliers were removed from data analysis during the cleaning process. Mode 
and weighted average scores as central tendency measures were calculated for prediabetes 
risk-test score by demographic characteristics of gender and race/ethnicity. Frequency and 
percentage of Medicare patients with prediabetes risk-test score of 5 or more for whom 
providers ordered laboratory screening tests (A1c, FPG, or 2hr-OGTT) were calculated. 
Mode as a measure of central tendency and percentages were calculated for prediabetes 
management types (DPP, Metformin, Diabetes Education, or a brief lifestyle counseling) 






























not fulfilled  (n=565), 
but diagnosis given as 
prediabetes
A1c>6.4%  (n=17), 
diabetes
normal A1c (<5.7%, 
n=323)







no lab test (n=1)
prior to 08/31/2019 
(n=17,502), excluded.




misdiagnosis of prediabetes by ICD-10 and laboratory test categories were calculated. The 
prevalence of misdiagnosis by ICD-10 codes and glucose laboratory tests was calculated.  
Result 
Prediabetes Risk-Test Score 
All 224 (100%) Medicare patients were found to have CDC-prediabetes risk-test 
scores of 5 or more with 7.2, 6.8, and 7.5 weighted average scores for both sexes, females, 
and males respectively (table 2). None of the 224 patients (100%) were laboratory screened 
for prediabetes by A1c, FPG, or 2hr-OGTT (Table 2). The frequency of prediabetes score 
steadily increases as a score increases from 5 to 7 and decreases as the score increases from 7 
to 9 in both genders with mode score of 7 (figure 3). As the prediabetes risk-test score 
increases from 7 to 9, within the same score, a greater number of males than females tend to 
be at risk for developing diabetes (figure 4). The majority of Medicare patients with scores 5 
or more are white (n=197, 87.95%) followed by Asian (n=8, 3.57%), other race (n=6, 
2.68%), declined (n=6, 2.68%), black (n=4, 1.79%), unable to determine race (n=3, 1.34%) 
(table 3, appendix D). 
Table 2.0  
          Medicare Patients Eligible for Prediabetes Screening by Laboratory Test  







% eligible for 
screening by 
A1c, FPG, or 
OGTT-2hr 
% screened by 
A1c, FPG, and 2hr-
OGTT 
224 224 100 0 
 





                     Figure 3. Frequency of Prediabetes Risk-Test Score Comparison Between 
                     Male and Female Medicare Patients.     
 
 
        Figure 4. Percentage of Medicare Patients for each prediabetes risk-test score by 
























































































 5 1 8 0 1 1 0 11 4.9 
 6 2 45 1 0 0 1 49 21.9 
 7 4 69 1 1 4 3 82 36.6 
 8 1 52 2 1 0 2 58 25.9 




8 197 4 3 6 6 224   
% 
 






7.2 6.6 7.2 7.3 6.7 7.0 7.2 
  
 
Misdiagnosis of Blood Glucose Level 
The prevalence of misdiagnosis of blood glucose level by either ICD-10 code or 
laboratory test was 45.2% (n=565). Most (n=201, 35.58%) of the misdiagnosis of blood 
glucose level was labeled as impaired fasting glucose with ICD-10 code R73.01, followed by 
other abnormal glucose (n=173, 30.62%, R73.09), prediabetes (n=163, 29.03%, R73.03), and 
impaired oral glucose (n=27, 4.78%, R73.02) (table 4, figure 5). Normal A1c level was the 
most (n=323, 57.17%) laboratory test misdiagnosed as abnormal blood glucose followed by 
normal random glucose (n=221, 39.02%), A1c>6.4% (n=17,3.01%), normal fasting plasma 
glucose (n=1, 0.18%) and diagnosis without laboratory test (n=1, 018%) (table 4, figure 6).  





        Figure 5. Frequency Distribution of Misdiagnosis of Blood Glucose Level by 
        ICD-10 Codes (n=565). 
 
         
           Figure 6. Frequency Distribution of Misdiagnosis of Blood Glucose Level by  




















































Table 4.0  
Misdiagnosis of Blood Glucose Level in Medicare Patients by ICD-10 and Laboratory Test 
Categories.  
Lab Categories ICD-10 codes 




















































































































































 No lab 
test 
0 0 1 0 1 0.18 
 Total 201 27 164 173 565  
 %  35.58 4.78 29.03 30.62   
Note. R73.01, Impaired fasting glucose; R73.09, other abnormal glucose; R73.03, 
Prediabetes; R73.02, Impaired Oral Glucose Tolerance. 
 
Management of Prediabetes 
All of Medicare patients (n=681, 100%) with prediabetes, as determined by, were not 
referred to a DPP, or individualized medical nutrition therapy. Only 21 patients (3.08%) were 
treated with metformin and 5 patients (0.73%) were referred to Diabetes Education (table 5). 
Due to restricted access to patients’ charts, the number of Medicare patients who received a 
brief lifestyle counseling could not counted (table 5).  




Table 5.0.  









Prediabetes Management Categories   
comment 









Number  681 0 21 5 0 unable to 
determine 
excluded 







3.8 0 3.1 0.7 0   
 
Note. Laboratory criteria to be eligible for management of prediabetes are A1c 5.7-6.4%, 
FPG 100-125mg/dl, or Random glucose 140-199mg/dl.  
 
 
        Figure 8. Medicare patients who received prediabetes management between 08/31/2019 









































Figure 9. Medicare Patients (n=26) who received prediabetes management in primary 
care setting between 08/31/2019 to 08/31/2020.  
Discussion 
Prediabetes Risk-Test Score 
The current quality assessment project’s data indicates that all 224 high-risk Medicare 
patients who visited CHI Franciscan primary clinics were not screened for prediabetes with 
the CDC/ADA diabetes risk test. This finding reflects a national survey report that only 27% 
of primary care providers (n=1256), including MDs and ARNPs, use the risk test to screen 
for prediabetes (Nhim et al., 2018) and only 6% of PCPs correctly identified all the risk 
factors that warrants prediabetes screening (Tseng et al., 2017). More than 50% (112 out of 
224) of the Medicare patients with the ADA Diabetes Risk test score of 5 or more, were not 
diagnosed with prediabetes (Ward, Hopkins & Shealy, 2021). This finding is in-line with the 
previous study that showed lack of screening in a primary care setting is one reason for 
delays in initiation or intensification of evidence-based treatment for diabetes (Grant et al., 
2004). The low screening for prediabetes indicates an urgent need to use the CDC/ADA 
diabetes risk test to help primary care providers identify high-risk patients to curb epidemics 
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Misdiagnosis of Blood Glucose Level 
The high prevalence (45.2%) of misdiagnosis of prediabetes could be due to the lack 
of knowledge around recommended laboratory parameters of prediabetes and incorrect use of 
ICD-10 codes as demonstrated by high misinterpretation of normal blood glucose level per 
ADA criteria (Alc<5.7% and random glucose<140mg/dl) as abnormal. The high prevalence 
(45.2%) of misdiagnosis of prediabetes found in this project is supported by another study 
where a survey regarding PCP knowledge indicated that only 17% correctly identified 
laboratory parameters for prediabetes based on FPG and A1c (Tseng et al., 2017). The lack of 
knowledge of PCPs about laboratory parameters could be due to inadequate preparation of 
undergraduate medical students (Khan, Wozniak, & Kirley, 2019). Moreover, the lack of 
uniformity in laboratory cut-off values of prediabetes between various organizations such as 
WHO and ADA (Bansal, 2015) and Diabetes Canada (Punthakee, Goldenberg & Katz, 2018) 
could add inconsistency in interpreting laboratory parameters and use of ICD-10 codes. 
Misdiagnosis may unnecessarily result in overdiagnoses that could burden society in return 
for limited clinical value (Yudkin & Montori, 2014). 
Management of Prediabetes 
The majority (96.2%) of the Medicare patients with prediabetes were not managed by 
referral to a DPP, metformin, referral to diabetes education, or medical nutritional therapy.  
All these patients were eligible for in-person or online DPP, the most effective evidence-
based lifestyle intervention known to prevent progression of prediabetes into diabetes. It is 
important to note that Medicare part B and Medicare Advantage cover costs related to 
glucose laboratory test screenings twice year and participation in the Medicare DPP (Center 
for Medicare and Medicaid Services, 2019). The lack of prediabetes management is 
consistent with a previous survey with 36 clinicians in a family medicine clinic where none 
referred patients with prediabetes to a DPP (Keck et al., 2019). The current zero referral is 




also supported by a national study that showed more than 75% of primary care providers do 
not refer to a DPP. This is attributed to a lack of awareness about the program's existence 
(Nhim et al., 2018) and the role of lifestyle change in prevention of diabetes (Khan, Wozniak 
& Kirley, 2019). The national survey by Nhim et al. showed 62% of primary care providers 
are not aware of the DPP, and 81% are not knowledgeable about the STAT (Screen, Test, Act 
Today) toolkit, use of which is associated with increased referral to the lifestyle change 
program.  
Once started, based on the Diabetes Prevention Program Outcome Study (DPPOS), 
metformin therapy should continue for the long-term, especially in prediabetic patients with a 
higher cut-off value of FPG 110-125 mg/dl and A1c 6.0-6.5% (Davidson, 2020). Providers 
should be aware that withdrawal of metformin treatment for a 1-to 2-week period may result 
in 64% more at risk of developing diabetes than those who have not started it (Diabetes 
Prevention Program Research Group, 2003).   
Conclusion 
This quality assessment project indicates potential need to improve clinical practice 
related to referral for prediabetes and patient outcomes within the CHI primary care clinics. 
The data showed that FMG primary care providers do not routinely screen for prediabetes 
using ADA/CDC prediabetes risk-test, order recommended laboratory tests for high-risk 
patients, refer confirmed prediabetes patients to the CDC-approved DPP suppliers, treat with 
metformin, and/or refer to diabetes education. As a result, 100% of CHI Medicare patients 
eligible for screening remained unscreened, making them at risk for undetected prediabetes or 
diabetes and its complications. FMG providers need to use consistent laboratory tests 
recommended by ADA with the correct interpretation of the results and correct ICD-10 codes 
to avoid the current high rate of misdiagnosis of prediabetes. Finally, FMG is encouraged to 
use these findings from the quality assessment to raise awareness of PCPs about the practice 




gap, use of DPP as a first-line treatment for prediabetes in Medicare patients. The FMG is 
also encouraged to start a pilot quality improvement project with selected providers and 
primary care clinics to implement a trial of the Plan-Do-Study-Act cycle (Knudsen et al., 
2019) of routine prediabetes screening, testing, and clinic-to-DPP referral (Appendix C). 
Providers can take advantage of the already established memorandum of understanding and 
business associate agreement between CHI Franciscan medical clinic and YMCA, the DPP 
supplier.  
Limitations 
The project has some limitations: 
1. The investigator could not detect undiagnosed cases, patients who fulfilled laboratory 
criteria for prediabetes but not given the diagnosis, because ICD-10 codes used to 
extract diagnosis of abnormal blood levels resulted only in diagnosed cases. 
2. The restricted access to patient charts limited access to provider's note on brief 
lifestyle counseling for prediabetes. 
3. Most patient charts extracted retrospectively did not contain physical activity 
information. It is unclear whether a history of physical activity was not asked or not 
documented during the patient visit. As a result, the investigator could not find 
physical activity details in terms of duration per session and number of sessions per 
week in the patient's chart. 
4. A survey might have been helpful to assess providers' knowledge and awareness on 
ADA/CDC risk-test, laboratory parameters of prediabetes, and DPP's availability. 
However, a follow-up survey was not part of the study protocol.  
5. Although 2hr-OGTT is the best diagnostic test for prediabetes diagnosis, based on a 
total of 7412 randomly selected undiagnosed adults from the National Health and 
Nutrition Examination Survey (Tucker, 2020), the current findings heavily relied on 




results of A1c, FPG, and random glucose tests. None of the study subjects had 
laboratory values for OGTT, even though the test agreement with A1c is only 25% 
and with FPG, 33.4% (Tucker, 2020). To avoid under or over-diagnosis of 
prediabetes, combining two of the three tests (A1c, OGTT-2hr, and FPG) produces a 
reliable diagnostic result (Gonzalez et al., 2020).  
6. Data on medical nutrition therapy was not found likely due to lack of reimbursement 
from Medicare for Medicare patients with prediabetes unless A1c is 6.4 or greater.  
7. Finally, this project's findings are not generalizable as the samples are not 
representative of all Medicare patients of all races, ethnicity, or gender.  
Implications 
The findings indicate that FMG primary care providers are not fully utilizing the best 
evidence-based diabetes prevention strategies. FMG needs to encourage their providers to 
screen, test, and refer high-risk prediabetes patients to DPP suppliers within their area. The 
lack of routine screening and testing for prediabetes contributes to the underutilization of 
diabetes educators who are skilled professionals able to reduce the risk of developing type II 
diabetes. The high prevalence of misdiagnoses of prediabetes blood glucose levels, suggests 
that reviewing current guidelines and reference ranges for fasting plasma glucose, A1c, oral 
glucose tolerance test, and random glucose tests would be beneficial for providers. Assigning 
the correct ICD-10 codes during the patient visit for abnormal blood glucose levels specific 
to the laboratory test would further improve diagnosis. Increasing provider's awareness of 
identifying high-risk patients using ADA/CDC prediabetes risk-test tool, preferably a 
screening tool embedded within the Epic, would prompt providers to place an order for 
specific recommended prediabetes blood glucose tests and increase referral of those Medicare 
patients with prediabetes to DDP suppliers, ultimately decreasing the incidence of diabetes at 
CHI. 
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Appendix A. Eligibility Criteria 
 
 
Medicare Diabetes Prevention Program (MDPP)
Beneficiary Eligibility Fact Sheet 
This checklist contains a summary of MDPP beneficiary eligibility requirements, as well as tips that MDPP suppliers 
can use to determine beneficiary eligibility. A full list of the beneficiary eligibility requirements can be found in the 
CY18 Medicare Physician Fee Schedule final rule at 42 C.F.R. 410.79(c).
REQUIREMENTS TO START SERVICES
To start MDPP services, beneficiaries must have:
Medicare Part B coverage through Original Medicare (Fee-for-Service) or a Medicare Advantage (MA) plan.
Results from one of three blood tests conducted within one year before the first core session:
• Hemoglobin A1c test with a value of 5.7-6.4% 
• Fasting plasma glucose test with a value of 110-125 mg/dl 
• Oral glucose tolerance test with a value of 140-199 mg/dl 
A body mass index (BMI) of at least 25, 23 if self-identified as Asian.
No history of type 1 or type 2 diabetes, with the exception of gestational diabetes.
No End Stage Renal Disease (ESRD).
Not received MDPP services previously.
REQUIREMENTS TO CONTINUE SERVICES
Represents when a beneficiary must meet a specific performance goal (i.e., attendance, weight loss) to be eligible to 
continue having coverage of services.
CORE SESSIONS CORE MAINTENANCE SESSIONS
Months 0-6 Months 7-12





3 sessions 3 sessions 3 sessions 3 sessions 3 sessions
Eligibility for Coverage of Core and Core Maintenance 
Sessions
• Eligible beneficiaries can participate in core and core 
maintenance sessions in the first 12 months 
regardless of attendance or weight loss.
Eligibility for Coverage of Ongoing Maintenance Sessions
• Interval 1: Beneficiaries must attend at least one in-
person core maintenance session during months 10-12 
and achieve or maintain 5% weight loss to proceed to 
interval 1.
• Intervals 2-4: Beneficiaries must attend at least two 
sessions (at least one in-person) in the previous interval 
and maintain 5% weight loss to go on to the next 
interval.
Note: An interval is a 3-month period tied to beneficiary performance and payment. 
1


















Height Weight  (lbs.)
4'10" 119-142 143-190 191+ 
4'11" 124-147 148-197 198+
5'0" 128-152 153-203 204+
5'1" 132-157 158-210 211+
5'2" 136-163 164-217 218+
5'3" 141-168 169-224 225+
5'4" 145-173 174-231 232+
5'5" 150-179 180-239 240+
5'6" 155-185 186-246 247+
5'7" 159-190 191-254 255+
5'8" 164-196 197-261 262+
5'9" 169-202 203-269 270+
5'10" 174-208 209-277 278+
5'11" 179-214 215-285 286+
6'0" 184-220 221-293 294+
6'1" 189-226 227-301 302+
6'2" 194-232 233-310 311+
6'3" 200-239 240-318 319+
6'4" 205-245 246-327 328+
1 Point 2 Points 3 Points




 1. How old are you?
Younger than 40 years (0 points)
40–49 years (1 point)
50–59 years (2 points)
60 years or older (3 points)
2. Are you a man or a woman?
Man (1 point) Woman (0 points)
3. If  you are a woman, have you ever been
 diagnosed w it h gest at ional diabetes?
Yes (1 point) No (0 points)
4. Do you have a mot her, fat her,  
 sist er, or brot her w it h diabet es?
Yes (1 point) No (0 points)
5. Have you ever been diagnosed 
 w it h high blood pressure?
Yes (1 point) No (0 points)
6. Are you physically act ive?
Yes (0 points) No (1 point)
7. What  is your weight  cat egory?
(See chart at right)
Writ e your score in 
t he boxes below
Tot al score:
You can reduce your risk for t ype 2 diabetes
  
Find out how you can reverse prediabetes and prevent or delay  
type 2 diabetes through a CDC-recognized lifestyle change pr ogram  
at https:/ /www.cdc.gov/diabetes/prevention/ lifestyle-program.
If  you scored 5 or higher
You are at increased risk for having prediabetes and are at high risk for type 2 diabetes. However, only your doctor can tell for sure if you  
have type 2 diabetes or prediabetes, a condition in which blood sugar levels are higher than normal but not high enough yet to be diagnosed 
as type 2 diabetes. Talk t o your doct or t o see if  addit ional t est ing is needed.
 
risk for prediabetes and type 2 diabetes. Also, if you are Asian American, you are at increased risk for type 2 diabetes at a lower weight (about 
15 pounds lower than weights in the 1 Point column). Talk to your doctor to see if you should have your blood sugar tested.
Adapted from Bang et al., Ann Intern Med 151:775-783, 2009. Original algorithm 
was validated without gestational diabetes as part of the model.
Risk Test provided by the American Diabetes Association 
and the Centers for Disease Control and Prevention.









Pat ient informat ion
Name Address
Gender City
Birth date (mm/dd/yy) State
Employer ZIP code
Preferred method of contact Phone
Preferred time to contact Health Insurance





Date:  _________________  Health care provider signature: __________________________________________
Authorization for release of health information [Insert your o rganization’s specific legal language here.]
Referral eligibility information: 
Criteria Reference range Result
¨ Body Mass Index (BMI)
¨ Blood test
• Hemoglobin A1C 




• Fasting plasma glucose 100-125 mg/dL _____________________
• 2-hour oral glucose tolerance test  140-199 mg/dL _____________________
        Date of blood test (mm/dd/yy):       ________________________________
¨ History of Gestational Diabetes
Date:  _________________  Pat ient or representat ive signature:  _____________________________________
(Basis of representative’s authority to sign on behalf of patient: ____________________________________________ )
National Diabetes Prevention Program (National 
Copyright © 2020. American Medical Association. All rights r eserved. 18-299724
Send to (program name): Fax/Email: 
DPP) lifestyle change program referral template
This resource can be used as a guide for creating a form to refer patients from clinical settings to a National DPP lifestyle
change program provider. The elements noted comprise key information to include in a referral and a sample template is 
also displayed below.
• Patient information: Name, contact information (address, phone, email), birth date/age, gender, health insurance,
employer, preferred method of contact, preferred time to contact.
• Health care provider information: Physician/provider name, practice name, practice contact name, practice
information (address, phone, fax, etc.)
• Other information: Date of referral, authorization information (language that meets your organization’ s specific legal
requirements for privacy and security, etc.), eligibility for program information (patient body mass index, medical
history and blood test results), signatures of physician/ordering provider and patient OR patient representative.
This resource is provided for informational purposes only and does not constitute legal advice. Please consult with a 
qualified legal advisor to create a resource for use within your organization.
Sa
ple




Appendix D. Prediabetes Score Frequency by Race 
 
         Frequency of Prediabetic Score Among Racial/Ethnic Groups (n=224) 
 
1 8 0 1 1 02
45
1 0 0 14
69
1 1 4 31
52
2 1 0 20
23










Asian White Black unable to
determine
other declined
Fr
eq
u
e
n
cy
Race
score 5
Score 6
Score 7
Score 8
score 9
